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Published by Elsevier Inc.CORRESPONDENCELetters to the EditorCan We STOP AF With
Cryoballoon Ablation?We read with interest the paper by Packer et al. (1), which
demonstrated lower recurrence of atrial ﬁbrillation (AF) after cry-
oballoon ablation (CB), as compared with antiarrhythmic drug
(AAD) therapy. Nevertheless, the data brings several questions:
1. Selection of few patients is unclear. The authors included,
against their study protocol (patients with >2 episodes of
paroxysmal atrial ﬁbrillation [PAF], without structural heart
disease, for whom at least 1 AAD failed).Figure 1 Box and Whisper Plots of Time to Duration of the Cryoballoon Ablation
Time and duration of the cryoballoon ablation procedure (A) and ﬂuoroscopy exposure time (
between 2005 and 2012. Improvement in success rate at 1-year follow up (FU) is related to b
lower number of comorbidities [such as hypertension, diabetes mellitus, metabolic syndrome2. 22% patients with “early persistent AF”. What is a deﬁnition
of “early persistent AF”? Are these PAF patients with high
AF-burden (2)?
3. 21 patients with coronary artery disease (CAD) and 1 pa-
tient without previous AAD failure;
4. 82 patients were enrolled for AAD treatment. Was the
selection of AAD randomized? Was any patient randomized
to previously failed AAD(s)? Continuation of previously
ineffective AAD(s) therapy had to result in an exaggerated
failure.
5. Even the most experienced operator needs time to adopt to
a new technology. The STOP-AF investigators randomized
163 patients in 26 centers for CB (i.e., approximately 6 patients
per center). After a cross-over, 228 patients (approximatelyProcedure and Fluoroscopy Exposure Time
B). (C) The number of patients in whom cryoballoon ablation was performed
etter selection of patients (paroxysmal atrial ﬁbrillation, not enlarged left atrium,
, impaired renal function]). *Only patients with 1-year follow up were included.
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13069 patients per center) had CB performed. The presented long
procedure and ﬂuoroscopy exposure times (371 and 63 min,
respectively) are characteristic for very early stage in learning
curve (3) (Fig. 1). Higher rates of permanent phrenic nerve
palsy (PNP) and pulmonary vein stenosis, than reported by
others (3–6), seem to further support our opinion. Even
though, CB was superior to AAD.
6. The use of a smaller cryoballoon is associated with a higher
incidence of PNP (5). Low CB temperature early during
the freezing cycle is a sensitive warning sign of impending
PNP (7). Persistent PNP can be avoided with interruption of
CB application in case of loss of phrenic nerve capture and/or
abrupt drop in CB temperature. Data on the mode of PN
monitoring during a procedure and the minimum tempera-
ture reached in patients with permanent PNP are missing.
7. CB outcome is worse in patients with non-pulmonary AF
(5), enlarged left atrium (6) and impaired renal function (6).
The presented 1-year success rate after a single CB proce-
dure (58%) was lower than previously reported (5) and more
recently reported (3,6) by single centers. Is it only of a result
of early operators’ experience or patients’ characteristics?
Data describing patients with CB-failure would be helpful to
understand the discrepancy.
8. CB eliminates focal triggers in pulmonary veins (PV)s but
cannot be expected to reach non-PV triggers or stop/reverse
structural remodeling in persistent AF. Repeated CB is
successful only in case of AF related to PV reconnection.
Thirty-one patients had repeated CB during the blanking
period. How many of these patients had PV reconnections?
Was the time, between index and repeated procedure, long
enough for local tissue healing after index CB? Otherwise,
the repeated procedure should had been postponed in time.
We believe that, as STOP-AF trial will have potentially high
inﬂuence on future recommendations and with the introduction of
a second generation of cryoballoons (with even higher rate of PV
strictures observed [8]), the above questions need clear answers.*Maciej Wójcik, MD
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Therapy of Paroxysmal Atrial
Fibrillation in Young Patients
With Low CHADS2 Score
Worth the Risk of Periprocedural and
Long-Term Adverse Events?
To alleviate palpitations and secondary detrimental effects in patients
with atrial ﬁbrillation (AF), the interventional AF therapies have
become a kind of gold-standard in the treatment of patients with
symptomatic AF, which is why about 50,000 procedures are per-
formed each year in the United States alone. Because pulmonary vein
isolation is less effective in patients with enlarged left atria with
permanent AF, there is a trend to treat younger patients with
paroxysmal AF with only moderate atrial structural changes. None-
theless, it is well known that patients with lone AF have low annual
rates of thromboembolismand low annual rates of heart failure during
conservative follow-up. According to the CHA2DS2-VASc score
(score to predict stroke in patients with atrial ﬁbrillation), patients
with low CHADS2 score do not require oral anticoagulants because
of the more benign prognosis in lone AF (1). In the prospective,
multicenter, randomized, controlled STOP AF cryoballoon trial (A
Clinical Study of the Arctic Front Cryoablation Balloon for the
Treatment of Paroxysmal Atrial Fibrillation), Packer et al. (2)
assessed the safety and the efﬁcacy of a novel cryoballoon ablation
technology compared with AF drug therapy in 245 patients with
paroxysmal AF and a mean CHADS2 score of 0.6. Mean age of all
patients was 56 years, 77% were male, with 93% New York Heart
Association (NYHA) none/I; 163 of the patients were assigned to
cryoablation and 82 to antiarrhythmic drugs. In this study the long-
term effectiveness in the cryoablation group was reported as 69.9%
after 12 months, with a mean ﬂuoroscopy exposure time of 63 min.
Regarding the adverse events during follow-up, only 1 adverse event
(1.2%) occurred in the drug therapy arm (transfusion because of
hemorrhage) compared with 32 adverse events (14.2%) in the cry-
oablation group, not regarding the 24 patients who suffered tempo-
rary phrenic nerve palsy. Five strokes, 4 transient ischemic attacks, 2
cases of tamponades, 2 myocardial infarctions, 3 transfusions, 2
atriovenous ﬁstulas, 2 pseudoaneurysms, 4 cases of persistent phrenic
